表紙
市場調查報告書

市場聚光燈:子宮癌症

Market Spotlight: Uterine Cancer

出版商 Datamonitor Healthcare 商品編碼 955905
出版日期 內容資訊 英文 44 Pages
商品交期: 最快1-2個工作天內
價格
市場聚光燈:子宮癌症 Market Spotlight: Uterine Cancer
出版日期: 2020年07月21日內容資訊: 英文 44 Pages
簡介

全球子宮癌症的新病例數,2019年的時刻估計為38萬5,200件,2028年預計增加到40萬4,300件。又在2019年時刻的5年以內既病例數估計130萬件,2028年預計增加到140萬件。

本報告提供全球子宮癌症市場調查,疾病的背景,治療方法,流行病學,上市的醫藥品,開發平台上的醫藥品,最近的動向和分析師的見解,今後預測,藥事法規方面重要的動向,許可證和資產收購的動向等資訊。

目錄

目錄

概要

重要的要點

疾病的背景

治療方法

  • 手術
  • 放射治療
  • 化療
  • 荷爾蒙療法
  • 緩和照護

流行病學

成藥

開發平台藥物

最近的動向和分析師的見解

  • Bavencio(2020年5月30日)
  • Trodelvy(2020年5月13日)
  • DKN-01(2020年4月23日)
  • Retifanlimab(2019年7月2日)
  • Trodelvy(2019年4月29日)
  • TAK-117(2019年3月20日)
  • Dostarlimab(2019年3月19日)
  • DKN-01(2019年3月18日)

今後主要的動向

法規方面主要的動向

  • 對應比較廣泛的適應症的Dostarlimab
  • FDA,核准Erleada的Keytruda/Lenvima組合式RTOR申請

成功的概率

許可證與資產取得契約

  • Tyligand,從Context取得Onapristone的ER權
  • 醫療產業的重要契約

商機

臨床試驗情勢

  • 各狀態的臨床試驗贊助者
  • 各階段的臨床試驗贊助者

參考文件

  • 藥方資訊

附錄

圖表清單

目錄
Product Code: DMKC0183133

This Market Spotlight report covers the uterine cancer market, comprising key marketed and pipeline drugs, clinical trials, recent events and analyst opinion, upcoming and regulatory events, probability of success, patent information, a 10-year disease incidence and prevalence forecast, and licensing and acquisition deals, as well as presenting drug-specific revenue forecasts.

Key Takeaways

Datamonitor Healthcare estimates that in 2019, there were 385,200 incident cases of uterine cancer in females worldwide, and expects that number to increase to 404,300 incident cases by 2028.

In the same year, there were an estimated 1.3 million five-year prevalent cases of uterine cancer worldwide, which is expected to increase slightly to 1.4 million cases by 2028.

Merck & Co's Keytruda and Eisai's Lenvima are the only FDA-approved drugs for uterine cancer. These drugs are administered via the intravenous and oral routes, respectively.

The majority of industry-sponsored drugs in active clinical development for uterine cancer are in Phase II, with only one drug in the NDA/BLA stage.

Therapies in active clinical development for uterine cancer focus on a wide variety of targets. These drugs are administered via the oral and intravenous routes.

High-impact upcoming events for drugs in the uterine cancer space comprise topline Phase III trial results and an estimated PDUFA date for dostarlimab.

The overall likelihood of approval of a Phase I solid tumors asset is 5.8%, and the average probability a drug advances from Phase III is 43.3%. Drugs, on average, take 9.5 years from Phase I to approval, compared to 9.4 years in the overall oncology space.

The distribution of clinical trials across Phase I-IV indicates that the vast majority of trials for uterine neoplasms have been in the early and mid-phases of development, with 95% of trials in Phase I-II, and only 5% in Phase III-IV.

The US has a substantial lead in the number of uterine neoplasms clinical trials globally, while Spain leads the major European markets.

Sanofi has the highest number of completed clinical trials for uterine neoplasms, with five trials.

AstraZeneca and Sanofi lead the industry sponsors with the highest overall number of clinical trials for uterine neoplasms.

TABLE OF CONTENTS

CONTENTS

OVERVIEW

KEY TAKEAWAYS

DISEASE BACKGROUND

TREATMENT

  • Surgery
  • Radiation therapy
  • Chemotherapy
  • Hormone therapy
  • Palliative care

EPIDEMIOLOGY

MARKETED DRUGS

PIPELINE DRUGS

RECENT EVENTS AND ANALYST OPINION

  • Bavencio for Uterine Cancer (May 30, 2020)
  • Trodelvy for Uterine Cancer (May 13, 2020)
  • DKN-01 for Uterine Cancer (April 23, 2020)
  • Retifanlimab for Uterine Cancer (July 2, 2019)
  • Trodelvy for Uterine Cancer (April 29, 2019)
  • TAK-117 for Uterine Cancer (March 20, 2019)
  • Dostarlimab for Uterine Cancer (March 19, 2019)
  • DKN-01 for Uterine Cancer (March 18, 2019)

KEY UPCOMING EVENTS

KEY REGULATORY EVENTS

  • Dostarlimab Submitted For (Relatively) Broad Endometrial Cancer Indication
  • FDA Issues Pair Of RTOR Approvals To Keytruda/Lenvima Combo, Erleada

PROBABILITY OF SUCCESS

LICENSING AND ASSET ACQUISITION DEALS

  • Tyligand Gets Onapristone ER Rights From Context
  • Deals Shaping The Medical Industry, August 2019

REVENUE OPPORTUNITY

CLINICAL TRIAL LANDSCAPE

  • Sponsors by status
  • Sponsors by phase

BIBLIOGRAPHY

  • Prescription information

APPENDIX

LIST OF FIGURES

  • Figure 1: Trends in incident cases of uterine cancer, 2019-28
  • Figure 2: Overview of pipeline drugs for uterine cancer in the US
  • Figure 3: Pipeline drugs for uterine cancer, by company
  • Figure 4: Pipeline drugs for uterine cancer, by drug type
  • Figure 5: Pipeline drugs for uterine cancer, by classification
  • Figure 6: Bavencio for Uterine Cancer (May 30, 2020): Phase II - TROPHIMMUN (Gestational Trophoblastic Neoplasias (GTN))
  • Figure 7: Trodelvy for Uterine Cancer (May 13, 2020): Phase I/II - Epithelial Cancer
  • Figure 8: DKN-01 for Uterine Cancer (April 23, 2020): Phase II - Gynecologic Malignancies (P204)
  • Figure 9: Dostarlimab for Uterine Cancer (March 19, 2019): Phase I/II - GARNET
  • Figure 10: DKN-01 for Uterine Cancer (March 18, 2019): Phase II - Gynecologic Malignancies (P204)
  • Figure 11: Key upcoming events in uterine cancer
  • Figure 12: Probability of success in the uterine cancer pipeline
  • Figure 13: Clinical trials in uterine cancer
  • Figure 14: Top 10 drugs for clinical trials in uterine cancer
  • Figure 15: Top 10 companies for clinical trials in uterine cancer
  • Figure 16: Trial locations in uterine cancer
  • Figure 17: Uterine cancer trials status
  • Figure 18: Uterine cancer trials sponsors by phase

LIST OF TABLES

  • Table 1: Incident cases of uterine cancer, 2019-28
  • Table 2: Five-year prevalent cases of uterine cancer, 2019-28
  • Table 3: Marketed drugs for uterine cancer
  • Table 4: Pipeline drugs for uterine cancer in the US
  • Table 5: Bavencio for Uterine Cancer (May 30, 2020)
  • Table 6: Trodelvy for Uterine Cancer (May 13, 2020)
  • Table 7: DKN-01 for Uterine Cancer (April 23, 2020)
  • Table 8: Retifanlimab for Uterine Cancer (July 2, 2019)
  • Table 9: Trodelvy for Uterine Cancer (April 29, 2019)
  • Table 10: TAK-117 for Uterine Cancer (March 20, 2019)
  • Table 11: Dostarlimab for Uterine Cancer (March 19, 2019)
  • Table 12: DKN-01 for Uterine Cancer (March 18, 2019)
  • Table 13: Historical global sales, by drug ($m), 2015-19
  • Table 14: Forecasted global sales, by drug ($m), 2020-24